Trial Profile
A phase I dose escalation study of tazemetostat in pediatric patients with IN1-deficient solid tumors
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 29 Sep 2015
Price :
$35
*
At a glance
- Drugs Tazemetostat (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 29 Sep 2015 New trial record
- 26 Sep 2015 According to Epizyme media release, company is planning to initiate this trial by fourth quarter of 2015.